Mizuho Securities USA LLC Grows Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Mizuho Securities USA LLC raised its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 42.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 18,868 shares of the medical equipment provider’s stock after purchasing an additional 5,662 shares during the quarter. Mizuho Securities USA LLC’s holdings in Zimmer Biomet were worth $1,993,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Dunhill Financial LLC raised its position in shares of Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 218 shares during the period. Stonebridge Financial Group LLC acquired a new stake in Zimmer Biomet during the fourth quarter worth about $25,000. Brooklyn Investment Group purchased a new position in shares of Zimmer Biomet in the 3rd quarter worth about $35,000. Kentucky Trust Co acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at about $39,000. Finally, OFI Invest Asset Management purchased a new stake in shares of Zimmer Biomet during the 4th quarter worth about $40,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.95% of the stock is currently owned by corporate insiders.

Zimmer Biomet Trading Up 0.5 %

Shares of NYSE ZBH opened at $111.31 on Tuesday. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The stock’s 50 day moving average price is $106.86 and its two-hundred day moving average price is $106.86. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $133.90. The stock has a market capitalization of $22.16 billion, a P/E ratio of 25.01, a PEG ratio of 1.95 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the company posted $2.20 EPS. On average, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.86%. Zimmer Biomet’s dividend payout ratio (DPR) is 21.57%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Truist Financial restated a “hold” rating and issued a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Stifel Nicolaus lifted their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. JMP Securities reaffirmed a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Finally, Royal Bank of Canada decreased their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.